View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
August 1, 2022

US FDA re-authorises EUA for Meridian’s Revogene SARS-CoV-2 test

Meridian Bioscience plans to start shipping the assay before the end of its fiscal fourth quarter.

The US F ood and Drug Administration (F DA) has re-authorised the emergency use authorization (EUA) for Meridian Bioscience Inc” target=”_blank”>Meridian Bioscience ’s Revogene SARS-CoV-2 molecular assay.

The regulator initially granted EUA for the Covid-19 molecular diagnostic test last November.

However, the company decided to delay the marketing of the assay so that its design could be modified to correctly detect the Omicron variant.

Meridian Bioscience Inc” target=”_blank”>Meridian Bioscience completed this development work and submitted an initial set of data to the F DA for validation of the redesigned assay’s performance in March.

Later, the company completed additional clinical studies to obtain EUA re-authorisation.

It intends to commence shipping of the assay before the end of its fiscal fourth quarter, which ends on 30 September.

A real-time RT-PCR test, Revogene SARS-CoV-2 has been designed to detect RNA from SARS-CoV-2 in anterior nasal, nasopharyngeal, oropharyngeal and mid-turbinate nasal swab samples collected from individuals who are suspected of having Covid-19 by their healthcare provider.

It runs on the company’s Revogene platform and can provide positive results in 47 minutes.

The company stated that the test has demonstrated good clinical performance, with 97.7% of negative and positive predictive agreements.

Meridian Bioscience Inc” target=”_blank”>Meridian Bioscience Diagnostics executive vice-president Tony Serafini-Lamanna said: “There continues to be demand for fast, accurate detection of Covid-19, especially considering the high transmissibility of these new variants and the upcoming respiratory season.

“We believe our Revogene SARS-CoV-2 assay and growing Revogene platform can help clinicians and health systems meet these demands now and in the future.”

The company’s fully automated Revogene molecular platform can easily integrate into any laboratory or health system and optimise the laboratory’s Covid-19 testing capacity in two steps.

Other F DA-approved tests that can run on the Revogene platform include Revogene Carba C, Revogene Strep A, Revogene C difficile and Revogene GBS LB.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Medical Device Network